Clinical Trial: Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07631013) titled 'Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions' on May 31.

Brief Summary: This is a phase 1, single-arm, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of TGFBR2 TROP2 CAR/IL15 NK cells in patients with high-risk oral premalignant lesions.

Study Start Date: Dec. 31, 2026

Study Type: INTERVENTIONAL

Condition: Squamous Cell Carcinoma

Intervention: DRUG: TROP2 CAR/IL-15 TGFBR2 KO NK cells

Participants will receive one of two doses of TROP2 CAR/IL-15 TGFBR2 KO NK injection on D0 and ev...